Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

EA Sausville, RD Lush, D Headlee, AC Smith… - Cancer chemotherapy …, 1998 - Springer
EA Sausville, RD Lush, D Headlee, AC Smith, WD Figg, SG Arbuck, AM Senderowicz…
Cancer chemotherapy and pharmacology, 1998Springer
Abstract UCN-01 (7-hydroxystaurosporine; NSC 638850) is a protein kinase antagonist
selected for clinical trial based in part on evidence of efficacy in a preclinical renal
carcinoma xenograft model. Schedule studies and in vitro studies suggested that a 72-h
continuous infusion would be appropriate. In rats and dogs, maximum tolerated doses
produced peak plasma concentrations of approximately 0.2–0.3 μM. However,
concentrations 10-fold greater are well tolerated in humans, and the compound has a …
Abstract
UCN-01 (7-hydroxystaurosporine; NSC 638850) is a protein kinase antagonist selected for clinical trial based in part on evidence of efficacy in a preclinical renal carcinoma xenograft model. Schedule studies and in vitro studies suggested that a 72-h continuous infusion would be appropriate. In rats and dogs, maximum tolerated doses produced peak plasma concentrations of approximately 0.2–0.3 μM. However, concentrations 10-fold greater are well tolerated in humans, and the compound has a markedly prolonged T1/2. Specific binding to human α1-acidic glyco-protein has been demonstrated. These findings reinforce the need to consider actual clinical pharmacology data in “real time” with phase I studies.
Springer